Common polygenic risk for autism spectrum disorder (ASD) is associated with cognitive ability in the general population
- PMID: 25754080
- PMCID: PMC4759203
- DOI: 10.1038/mp.2015.12
Common polygenic risk for autism spectrum disorder (ASD) is associated with cognitive ability in the general population
Abstract
Cognitive impairment is common among individuals diagnosed with autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD). It has been suggested that some aspects of intelligence are preserved or even superior in people with ASD compared with controls, but consistent evidence is lacking. Few studies have examined the genetic overlap between cognitive ability and ASD/ADHD. The aim of this study was to examine the polygenic overlap between ASD/ADHD and cognitive ability in individuals from the general population. Polygenic risk for ADHD and ASD was calculated from genome-wide association studies of ASD and ADHD conducted by the Psychiatric Genetics Consortium. Risk scores were created in three independent cohorts: Generation Scotland Scottish Family Health Study (GS:SFHS) (n=9863), the Lothian Birth Cohorts 1936 and 1921 (n=1522), and the Brisbane Adolescent Twin Sample (BATS) (n=921). We report that polygenic risk for ASD is positively correlated with general cognitive ability (beta=0.07, P=6 × 10(-7), r(2)=0.003), logical memory and verbal intelligence in GS:SFHS. This was replicated in BATS as a positive association with full-scale intelligent quotient (IQ) (beta=0.07, P=0.03, r(2)=0.005). We did not find consistent evidence that polygenic risk for ADHD was associated with cognitive function; however, a negative correlation with IQ at age 11 years (beta=-0.08, Z=-3.3, P=0.001) was observed in the Lothian Birth Cohorts. These findings are in individuals from the general population, suggesting that the relationship between genetic risk for ASD and intelligence is partly independent of clinical state. These data suggest that common genetic variation relevant for ASD influences general cognitive ability.
Conflict of interest statement
AMM has received financial support from Pfizer (formerly Wyeth), Janssen and Lilly. AMM has done consultancy work for Roche Pharmaceuticals. The other authors declare no conflict of interest.
Figures
References
-
- 2Larsson H, Dilshad R, Lichtenstein P, Barker ED. Developmental trajectories of DSM-IV symptoms of attention-deficit/hyperactivity disorder: genetic effects, family risk and associated psychopathology. J Child Psychol Psychiatry 2011; 52: 954–963. - PubMed
-
- 3Lichtenstein P, Carlstrom E, Rastam M, Gillberg C, Anckarsater H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry 2010; 167: 1357–1363. - PubMed
-
- 4Sherman DK, McGue MK, Iacono WG. Twin concordance for attention deficit hyperactivity disorder: a comparison of teachers' and mothers' reports. Am J Psychiatry 1997; 154: 532–535. - PubMed
Publication types
MeSH terms
Grants and funding
- 104036/WT_/Wellcome Trust/United Kingdom
- CZD/16/6/CSO_/Chief Scientist Office/United Kingdom
- MR/K026992/1/MRC_/Medical Research Council/United Kingdom
- 104036/Z/14/Z/WT_/Wellcome Trust/United Kingdom
- G0700704/MRC_/Medical Research Council/United Kingdom
- BB/F019394/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- ETM/55/CSO_/Chief Scientist Office/United Kingdom
- CZB/4/505/CSO_/Chief Scientist Office/United Kingdom
- CZD/16/6/4/CSO_/Chief Scientist Office/United Kingdom
- MC_PC_U127561128/MRC_/Medical Research Council/United Kingdom
- HR03006/CSO_/Chief Scientist Office/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
